查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球造影劑注射器市場
市場調查報告書
商品編碼
1146446

2022-2029 年全球造影劑注射器市場

Global Contrast Media Injectors Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 250 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

造影劑注射器的全球市場規模預計將在 2021 年達到 XX 萬美元，在 2029 年達到 XX 萬美元，在預測期間（2022-2029 年）以 6.8% 的複合年增長率增長。

造影劑注射器是一種醫療設備，用於將造影劑注入人體，以在醫學成像期間增強組織的可見性。技術進步將促進造影劑使用的自動控制、自動數據收集和每位患者的個性化劑量。

市場動態

造影劑注射器市場的增長受到創傷增加、成像中心數量增加、老年人口增加以及研發活動的推動。

心血管疾病患病率上升預計將推動市場增長

在預測期內，技術進步和放療使用的增加預計將推動市場擴張 據世界衛生組織 (WHO) 稱，心血管疾病是全球第一大死因。每年約有 1790 萬人患有心血管疾病。超過五分之四的心血管疾病死亡是由於心髒病發作和中風，其中三分之一的死亡發生在 70 歲之前。越來越多的需要診斷的心血管疾病患者導致對造影劑注射器的需求增加。

此外，市場參與者正在採取產品發布和合作等市場策略。例如，2021 年 12 月，Qaelum NV 將與烏爾姆的 Ulrich GmbH & Co.KG 合作，將公司先進的造影劑管理解決方案與 Ulrich Medical 的造影劑注射器相結合，以滿足醫院和成像網絡的需求，並宣布支持。同樣在 2020 年 5 月，德國醫療技術公司 Ulrich Medical 在芝加哥的 RSNA 推出了一款專為美國市場設計的 CT 運動造影劑注射器。 FDA 與 GE Healthcare 合作批准和銷售。

造影劑的副作用阻礙市場增長

但是，X 射線造影劑的副作用從輕微的不便（如瘙癢）到危及生命的緊急情況。造影劑引起的腎病是與使用靜脈內或動脈內造影劑相關的副作用。此外，還有遲發性過敏反應、過敏反應、皮膚反應等副反應。

COVID-19 影響分析

COVID-19 的出現對全球造影劑注射器市場產生了相當大的影響。 2020年4月發表在放射學雜誌上的一篇文章發現，在大流行期間，由於經濟失衡，醫療保健支出下降。放射學公司從未經歷過因需要限制獲得診斷成像而加劇的經濟衝擊。擁有大量門診患者的診所感受到了這些變化的最大影響，但所有圖像處理量都減少了。放射科診所應該預計成像吞吐量會減少 50%-70%，持續至少 3-4 個月，具體取決於診所位置和每個地區 COVID-19 大流行的嚴重程度。在大流行期間，許多患者將難以獲得醫療保健，這將對市場產生負面影響。

同時，到 2022 年，情況已經從 COVID-19 中恢復過來，幾乎所有患者都可以使用先進的醫療設施。完善的診斷中心和服務患者正在推動全球市場的發展。

細分分析

預計 CT 細分市場在預測期間（2022-2029 年）將以最快的複合年增長率增長。

預計 CT 細分市場將在預測期內提振市場。根據 2022 年 4 月發表在《醫療器械證據與研究》上的一篇文章，全球對比增強 CT（計算機斷層掃描）檢查的數量正在逐年增加。掃描儀技術的進步和多排 CT (MDCT) 的可用性使執行掃描的時間更加簡潔。在此背景下，開發了一種新的 CT 注射裝置，在保持活塞式註射裝置（如 Stellant CT 注射裝置）的液體傳輸性能的同時提高了時間效率。現在您可以更專注於您的患者，而無需花費太多很多時間處理它們。新的計量系統在技術流體輸送性能方面與當前的活塞系統非常相似，但主要區別在於工作流程的特點。

此外，市場參與者正在應用收購和產品發布等市場策略。例如，2021 年 12 月，Qaelum NV 與烏爾姆的 Ulrich GmbH & Co. KG 達成協議，將其造影劑管理技術與 Ulrich 醫用造影劑注射器相結合，以滿足醫院和成像網絡的需求。

區域分析

北美在全球造影劑市場佔有最大份額

北美在造影劑注射器市場中占主導地位，預計在預測期內將呈現類似趨勢。由於先進的醫療基礎設施、老齡化社會的進步、技術進步、產品批准等，估計在預測期間（2022-2029 年）將佔據相當大的市場規模。

大量主要參與者的存在以及產品和服務的現成可用性推動了市場。例如，Ulrich Medical 提供用於計算機斷層掃描 (CT) 和磁共振成像 (MRI) 的造影劑注射器。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 技術進步
      • 激活研發
    • 限制因素
      • 造影劑注射器價格飆升
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 法律法規分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按正面數

  • 單頭
  • 雙頭
  • 三頭

第 8 章按設備

  • CT
  • 血管造影
  • 核磁共振
  • 其他

第 9 章。可移植性

  • 固定式
  • 可移動

第 10 章按應用程序

  • 介入心髒病學
  • 腫瘤學
  • 神經內科
  • 介入放射學
  • 其他

第 11 章，最終用戶

  • 診斷中心
  • 醫院
  • 其他

第 12 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 13 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 14 章公司簡介

  • Bracco Imaging
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Guerbet Group
  • Imaxeon
  • Medtronic
  • Nemoto
  • M. Schilling GmbH Medical Products
  • PTM-Network Services GmbH
  • Shenzhen Anke High-Tech
  • Ulrich Medical
  • Vivid Imaging

第15章 全球造影劑市場-DataM

簡介目錄
Product Code: DMMD108

Market Overview

The global contrast media injectors market size was growing at a CAGR of 6.8% during the forecast period (2022-2029).

Contrast media injectors are medical devices utilized for injecting contrast media into the human body to increase the visibility of tissues for medical imaging procedures. Due to technological advancements, automated systems control the amount of contrast media agents used and promote automated data collection and personalized doses for each patient.

Market Dynamics

The contrast media injectors market growth is driven by the rise in trauma cases, rising diagnostic imaging centers, increasing the geriatric population, and research and development activities.

The rising prevalence of cardiovascular diseases is expected to drive the market growth

Technological advancement and rising radiological procedures are expected to boost the market over the forecast period. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70. The increasing number of patients with cardiovascular disease that need to be diagnosed leads to increasing demand for contrast media injectors.

In addition, the market players are adopting market strategies, including product launches and collaboration. For instance, in December 2021, Qaelum NV partnered with Ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with the contrast media injectors of Ulrich Medical to support the needs of hospitals and imaging networks. Also, in May 2020, Ulrich Medical, a German medical technology company, presented a version of its CT motion contrast media injector designed for the American market at the RSNA in Chicago. It was authorized by the FDA and vended in cooperation with GE Healthcare.

The adverse effects of contrast media will hamper the growth of the market

However, side effects of radiographic contrast media range from mild inconveniences, such as itching, to a life-threatening emergency. Contrast-induced nephropathy is an adverse reaction associated with the use of intravenous or intra-arterial contrast material. In addition, adverse reactions such as delayed anaphylactic reactions, allergic reactions, and cutaneous reactions.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global contrast media injectors market. According to an article published in Radiology Journal in April 2020, during the pandemic, economic imbalances resulted in decreased healthcare expenditures. Radiology companies have never experienced an economic shock that is simultaneously worsened by the need to limit the availability of imaging. Outpatient-heavy practices felt the biggest impact of these changes, but all imaging volumes decreased. Radiology practices should anticipate a 50%-70% decrease in imaging volume that lasts a minimum of 3-4 months, as per the location of practice and the stringency of the COVID-19 pandemic in each region. During the pandemic, many patients faced access to healthcare treatment, leads to a negative impact on the market.

On the other hand, in 2022, the situation is recovering COVID- 19, and mostly every patient can access advanced healthcare facilities. Diagnostic centers are opening properly, and giving services to patients boosts the market worldwide.

Segment Analysis

The CT segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The CT segment is expected to boost the market over the forecast period. As per the article published in Medical Devices Evidence and Research in April 2022, The number of contrast-enhanced computed tomography (CT) examinations is rising worldwide each year. Because of the development of scanner technology and Multidetector CT (MDCT) availability, the time to conduct the scan has become more concise. A new CT injection system has been developed to maintain the fluid delivery benefits of a piston-based system (such as the Stellant CT injection system) but with the most elevated conceivable time efficiency, permitting the radiographer to spend less time handling the injector and disposables and more time concentrating on the patient. While the technical fluid delivery performance is very similar between this novel injection system and the current piston-based system, the major differences are in the workflow features.

In addition, the market players are applying the market strategies such as acquisition and product launches. For instance, in December 2021, to meet the demands of hospitals and imaging networks, Qaelum NV agreed with Ulrich GmbH & Co. KG in Ulm to merge their Contrast Management technology with Ulrich medical's contrast media injectors.

Geographical Analysis

North America region holds the largest market share of the global contrast media injectors market

North America dominates the market for contrast media injectors and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, a rising aging population, technological advancement and approval of products.

As per the American Association for the Surgery of Trauma data, in 2020, trauma accounted for nearly 40 Mn homicide and suicide deaths each year in the US that occurred due to trauma. The rising number of patients with trauma leads to increasing demand for contrast media injectors in the North American region.

In addition, the presence of a large number of key players and easily availability of products and services drive the market. For instance, Ulrich medical offers contrast media injectors for usage in computed tomography (CT) and magnetic resonance imaging (MRI).

Competitive Landscape

The contrast media injectors market is a moderately competitive presence of local and global companies. Some key players contributing to the market's growth are Bracco Imaging, Guerbet Group, Imaxeon, Medtronic, Nemoto, M. Schilling GmbH Medical Products, PTM-Network Services GmbH, Shenzhen Anke High-Tech, Ulrich Medical, Vivid Imaging among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the global contrast media injectors market's growth.

For instance,

  • In December 2021, Guerbet and Bracco Imaging collaborated for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent.

Bracco Imaging

Overview:

Bracco Imaging is an Italian healthcare multinational company founded in 1927 and headquartered in Milan, Italy. The company developed specific contrast injectors for intravenous procedures in CT and MRI and for intraarterial procedures in Cardiac and or Peripheral intervention.

Product Portfolio:

CT Expres: It is a 3D Contrast Media Delivery System that is used for controlled automatic management, on the venous side of contrast media and saline, to human matters while experiencing examination by means of computed tomography (CT) scanner.

The global contrast media injectors market report would provide access to approximately 75+ market data tables, 75+ figures, and in the range of 250 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement
      • 4.1.1.2. Increase research and development activities
    • 4.1.2. Restraints:
      • 4.1.2.1. Rising cost contrast media injectors
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Number of Heads

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 7.1.2. Market Attractiveness Index, By Number of Heads
  • 7.2. Single-Head*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Dual-Head
  • 7.4. Triple-Head

8. By Devices

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 8.1.2. Market Attractiveness Index, By Devices
  • 8.2. CT*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Angiography
  • 8.4. MRI
  • 8.5. Others

9. By Portability

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 9.1.2. Market Attractiveness Index, By Portability
  • 9.2. Fixed*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Movable

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Interventional Cardiology*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Oncology
  • 10.4. Neurology
  • 10.5. Interventional Radiology
  • 10.6. Others

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Diagnostic Centres*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Hospitals
  • 11.4. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Treatment type Benchmarking

14. Company Profiles

  • 14.1. Bracco Imaging*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Guerbet Group
  • 14.3. Imaxeon
  • 14.4. Medtronic
  • 14.5. Nemoto
  • 14.6. M. Schilling GmbH Medical Products
  • 14.7. PTM-Network Services GmbH
  • 14.8. Shenzhen Anke High-Tech
  • 14.9. Ulrich Medical
  • 14.10. Vivid Imaging

LIST NOT EXHAUSTIVE

15. Global Contrast Media Injectors market- DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us